



September 2024

Our Vision is to Improve Yours

With topical ophthalmic therapies that are easier to use and easier to live with



Forward-looking Statements

Except for historical information, all the statements, expectations and assumptions contained in this presentation are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our products, product candidates and platform technology. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission.

In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our and our licensees' clinical trials, including, but not limited to, the costs, design, initiation and enrollment, timing, progress and results of such trials; the timing and our licensees' ability to submit applications for, obtaining and maintaining regulatory approvals for Mydcombi, clobetasol propionate and our product candidates; the potential advantages of Mydcombi, clobetasol propionate and our product candidates and platform technology and potential revenues from licensing transactions; the rate and degree of market acceptance and clinical utility of Mydcombi, clobetasol propionate and our product candidates; our estimates regarding the potential market opportunity for Mydcombi, clobetasol propionate and our product candidates; reliance on third parties to develop and commercialize Mydcombi™, clobetasol propionate and certain of our product candidates; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for Mydcombi, clobetasol propionate and our product candidates; intellectual property risks; changes in legal, regulatory, legislative and geopolitical environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and our competitive position.

Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements.

Eyenovia: Our Vision is to Improve Yours



Optejet®: Topical Eye Medication Platform Technology

Designed for ease of use, enhanced tolerability, and compliance through digital technology


FDA-Approved Products

- Mydcombi™ for pupil dilation
- Clobetasol for post-surgical inflammation and pain

Multiple Late-Stage Candidates in the Optejet

- Cyclosporine/Optejet (EYEN-510) for dry eye
SGN Nanopharma
- Fonadelpar/Optejet (EYEN-520) for dry eye
Senju Pharmaceuticals
- Clobetasol/Optejet (EYEN-530) for acute dry eye
Formosa Pharmaceuticals
- MicroPine (atropine/Optejet) for pediatric progressive myopia. Arctic Vision in China and Korea

Recent and Near-Term Anticipated Corporate Highlights



MicroPine Is Our Premier Near-Term Opportunity in the Multi-Billion Dollar Pediatric Progressive Myopia Market


(Atropine Ophthalmic Spray)




 \$3.0B market in the U.S. and China

Major Clinical Milestone expected 4Q 2024 

 **Optejet Technology**
Easy to use and self-administer with digital capability to track adherence and compliance

Strong IP, Non-Substitutable
Unique FDA form with design and method patents through 2041 

 **Recognized Unmet Medical Need**
Current options are not appropriate for all patients and do not eliminate progression risk

In-House Manufacturing
CMO manufactures drug products
Device and Sterile Fill and Finish by Eyenovia 

Facing the Myopia Epidemic

Experts around the world are tackling the challenge of myopia on multiple fronts. An overview of current behavioral, pharmacological, and optical approaches.

MYOPIA: A GLOBAL EPIDEMIC



An overview of the problem and efforts to address it.


BY NEESURG MEHTA, MD; AND ANGIE WEN, MD

FORBES > INNOVATION > HEALTHCARE

The Growing Global Epidemic Of Childhood Myopia: Is Atropine The Answer?

Progressive Myopia is a Global Epidemic That Can Lead to Vision Loss and Blindness if Not Controlled

- Begins in early childhood, with genetic link or environmental factors¹
- Elongation of the eye with morbidity and vision problems²
- Currently no FDA-approved drug therapies to slow myopia progression




¹ Jones LA, Sinnott LT, Mutti DO, Mitchell GL, Moeschberger ML, Zadnik K. Parental history of myopia, sports and outdoor activities, and future myopia. Invest Ophthalmol Vis Sci. 2007 Aug;48(8):3524-32.

² Eye and Contact Lens. 2004; 30

³ Theophanous C. Myopia Prevalence and Risk Factors in Children. Clinical Ophthalmology. December 2018. U.S. Census Bureau, Current Population Survey, Annual Social and Economic Supplement, 2019.

Approximately 5 Million Children are at High Risk for Vision Loss Without Effective Intervention

Predicted Myopic Progression Rates of Untreated 9-Year-Old Children Over 3 Years



Lenses are Today the Only FDA-Approved Treatment

Approved Devices



Over 75% of optometrists, however, feel that using contact lenses in patients under 10 years of age is not appropriate. Microbial keratitis being a serious concern for contact lens wearers.¹



A 2012 study showed that two thirds of children did not comply with wearing their vision correcting spectacles due to various reasons (Dislike, Lost/Broken, Feel Unnecessary, Teasing)²

Efficacy

“Evaluating children who were prescribed MiSight® 1 day at the study’s initiation, 23% of eyes after year six displayed a total refractive change of less than -0.25D (spherical equivalent)...”

Approximate cost to patient \$1800 per year for visits and lenses [\$700 lens cost to physician]

“Essilor® Stellest® lenses slow down myopia progression by 67% on average, compared to single vision lenses...”

Approximate cost to patient \$1800 to \$2600 per year depending on severity [\$200 lens cost to physician]

Topical atropine has been observed to slow myopia progression in children¹

Atropine for the Treatment of Childhood Myopia

Wei-Han Chua, FRCSEd(Ophth), FAMS,^{1,2} Vivian Balakrishnan, FRCSEd, FRCOphth,¹ Yiong-Huak Chan, PhD,³ Louis Tong, FRCSEd,¹ Yvonne Ling, FRCSEd, FRBOptom,¹ Boon-Long Quah, FRCSEd, MMed(Ophth),¹ Donald Tan, FRCSEd, FRCOphth,¹

Purpose: To evaluate the efficacy and safety of topical atropine, a non-sedating, slow-releasing formulation of atropine, in slowing the progression of myopia and ocular axial elongation in Asian children.

Design: Parallel-group, placebo-controlled, randomized, double-masked trial.

Participants: Four hundred children aged 6 to 12 years with refractive error of -0.50 diopters (D) and astigmatism of -1.50 D or less.

Intervention: Participants were assigned with equal probability to receive eye drops once nightly for 2 years. Only 1 eye of each subject was chosen through randomization.

Main Outcome Measures: The main efficacy outcome measures were refractive error as measured by cycloplegic autorefractometry and change in ocular axial length as measured by ocular coherence tomography.

Results: Three hundred forty-six (86.5%) children completed the 2-year study. The mean change in spherical equivalent (SE) and axial length over 2 years was -0.38 ± 0.38 mm, respectively, in the atropine-treated eyes, myopia progression in the axial length remained essentially unchanged compared with baseline (-0.02 D myopia progression and axial elongation between the 2 groups were -0.92 D to -0.77 D; P < 0.001) and 0.40 mm (95% confidence interval, 0.35-0.45 mm; P < 0.001) compared with the placebo-treated eyes.

Conclusions: Topical atropine was well tolerated and effective in slowing moderate myopia and ocular axial elongation in Asian children. *Ophthalmology* 2016;125:1033-1041.



Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2

Myopia Control with Atropine 0.01% Eyedrops

Aubrey Chia, FRANZCO, PhD,^{1,2} Qing-Shu Lu, PhD,^{3,4} Donald Tan, FRCS, FRCOphth,^{1,2}

Purpose: To compare the safety and efficacy of different concentrations of atropine eye drops in slowing myopia progression over 5 years.

Design: Randomized, double-masked clinical trial.

Participants: A total of 400 children originally randomized to receive atropine 0.5%, 0.025%, or 0.01% atropine eye drops in a 2:2:1 ratio.

Methods: Children received atropine for 24 months (phase 1), after which medication was discontinued for 6 months (phase 2), after which medication was restarted on atropine 0.01% for a further 24 months (phase 3).

Main Outcome Measures: Change in spherical equivalent and axial length over 5 years.

Results: There was a dose-related response in phase 1 with a greater effect in higher dose groups. Myopia progression in phase 2 (washout) was similar to phase 1. Myopia progression in the 0.01% group persisted during phase 3, with overall myopia progression at the end of 5 years being lowest in this group (-1.38 ± 0.98 D; 0.75 ± 0.48 D, 0.1% (-1.83 ± 1.16 D, P = 0.003; 0.85 ± 0.53 mm, P = 0.144) and 0.5% (-1.98 ± 1.10 D, P = 0.075) groups. Atropine 0.01% also caused minimal pupil dilation (0.8 mm), minimal accommodation (2-3 D), and no near visual loss compared with higher doses.

Conclusions: Over 5 years, atropine 0.01% eyedrops were more effective in slowing myopia progression with less visual side effects compared with higher doses of atropine. *Ophthalmology* 2016;125:1033-1041.

Conclusions: Over 5 years, atropine 0.01% eyedrops were more effective in slowing myopia progression with less visual side effects compared with higher doses of atropine. *Ophthalmology* 2016;125:1033-1041.

Conclusions: Over 5 years, atropine 0.01% eyedrops were more effective in slowing myopia progression with less visual side effects compared with higher doses of atropine. *Ophthalmology* 2016;125:1033-1041.

Conclusions: Over 5 years, atropine 0.01% eyedrops were more effective in slowing myopia progression with less visual side effects compared with higher doses of atropine. *Ophthalmology* 2016;125:1033-1041.



Low-Concentration Atropine for Myopia Progression (LAMP) Study

A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control

Jason C. Yam, FCOphthHK, FRCSEd(Edn),¹ Yuning Jiang, MMed,¹ Shu Min Tang, PhD,¹ Antony K.P. Lau, MSc,¹ Joyce J. Chan, MRCSEd(Ophth),¹ Emily Wong, MRCB, MRCSEd(Edn),¹ Simon T. Ko, FCOphthHK, FHKAM(Ophth),² Alex L. Young, MMedSc(Hons), FRCOphth,^{1,3} Clement C. Tham, FCOphthHK, FRCOphth,¹ Li Ju Chen, MRCSEd(Ophth), PhD,^{1,3} Chi Pui Pang, DPhil¹

Purpose: Low-concentration atropine is an emerging therapy for myopia progression, but its efficacy and optimal concentration remain uncertain. Our study aimed to evaluate the efficacy and safety of low-concentration atropine eye drops at 0.05%, 0.025%, and 0.01% compared with placebo over a 1-year period.

Design: Randomized, placebo-controlled, double-masked trial.


Participants: A total of 438 children aged 4 to 12 years with myopia of at least -1.0 diopter (D) and astigmatism of -2.5 D or less.

Methods: Participants were randomly assigned in a 1:1:1:1 ratio to receive 0.05%, 0.025%, and 0.01% atropine eye drops, or placebo eye drops, respectively, once nightly to both eyes for 1 year. Cycloplegic refraction, axial length (AL), accommodation amplitude, pupil diameter, and best-corrected visual acuity were measured at baseline, 2 weeks, 4 months, 8 months, and 12 months. Visual Function Questionnaire was administered at the 1-year visit.


Main Outcome Measures: Changes in spherical equivalent (SE) and AL were measured, and their differences among groups were compared using generalized estimating equation.

Results: After 1 year, the mean SE change was -0.27 ± 0.61 D, -0.46 ± 0.45 D, -0.59 ± 0.61 D, and -0.81 ± 0.63 D in the 0.05%, 0.025%, and 0.01% atropine groups, and placebo groups, respectively (P < 0.001), with a respective mean increase in AL of 0.20 ± 0.25 mm, 0.29 ± 0.20 mm, 0.36 ± 0.29 mm, and 0.41 ± 0.22 mm (P < 0.001). The accommodation amplitude was reduced by 1.98 ± 2.82 D, 1.61 ± 2.61 D, 0.28 ± 0.94 D, and 0.92 ± 2.91 D, respectively (P < 0.001). The pupil sizes under photopic and mesopic conditions were increased respectively by 1.03 ± 1.02 mm and 0.58 ± 0.63 mm in the 0.05% atropine group, 0.76 ± 0.90 mm and 0.43 ± 0.61 mm in the 0.025% atropine group, 0.49 ± 0.80 mm and 0.23 ± 0.46 mm in the 0.01% atropine group, and 0.13 ± 1.07 mm and 0.02 ± 0.55 mm in the placebo group (P < 0.001). Visual acuity and vision-related quality of life were not affected in any group.

Conclusions: The 0.05%, 0.025%, and 0.01% atropine eye drops reduced myopia progression along a concentration-dependent response. All concentrations were well tolerated without an adverse effect on vision-related quality of life. Of the 3 concentrations used, 0.05% atropine was most effective in controlling SE progression and AL elongation over a period of 1 year. *Ophthalmology* 2018;127:12-22 © 2018 by the American Academy of Ophthalmology.



LAMP-1 Results
438 Subjects





ATOM-1 Results
400 Subjects

There are currently no FDA-approved pharmaceutical options



1. Chia A, Chua WH, Cheung YB, et al. Atropine for the treatment of childhood Myopia: Safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). *Ophthalmology* 2012;119:347-354

Eye Doctors are using Compounded Atropine Off-label to Treat Myopia Patients



MICROPINE (atropine ophthalmic spray)

The Premier Drug+Device Product Candidate for Progressive Myopia



Target Product Profile

- 60% reduction in myopia progression with minimal rebound after one year
- One spray per each eye daily; easy enough for children to use without supervision
- Comfortable to instill with minimal impact on the ocular surface
- Very low systemic exposure, an important consideration for a multi-year therapy in small children
- Optecare™ compliance system provides dosing reminders and product use history for doctors to improve treatment success
- Estimated 90% margins based on NSP of \$200/month with COGS of \$20/month


CHAPERONE

The Single Phase 3 Trial Required for FDA Approval

- Three arms dosed with 8 microliter ophthalmic spray: placebo, 0.01%, and 0.1% atropine
- Myopic children in the U.S. between the ages of 3 and 13 at risk for progression
- MicroPine self-administered with the Optejet as one spray in each eye at night
- Three years to efficacy endpoint – myopia progression of less than 0.5 diopters
- Well tolerated; adverse events are infrequent and mild with no SAEs related to drug treatment. Therapy compliance appears higher than what has been seen historically with eye drop studies.

Treatment Compliance via the Optecare™ System is What Makes MicroPine Special

- Only MicroPine comes with built-in Optecare™ technology to track and communicate patient compliance data
- In CHAPERONE, the daily treatment compliance of the first 28 subjects was well above what was predicted
- Treatment adherence and compliance is typically a primary determinant of therapy success
- Payers are strongly motivated to include therapies on formulary that improve outcomes¹



Potential Peak Sales of Over One Billion Dollars

	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036
Number of Potential Users	5,000,000	5,050,000	5,100,500	5,151,505	5,203,020	5,255,050	5,307,601	5,360,677	5,414,284	5,468,426
Approx. Market Share	0.5%	1%	2%	4%	6%	7%	8%	9%	10%	10%
Cartridge Units	150,000	375,000	937,500	1,640,625	2,460,938	3,076,172	3,537,598	4,068,237	4,678,473	5,380,244
Product Price (Net of Rebates)	\$200.00	\$200.00	\$200.00	\$200.00	\$200.00	\$200.00	\$200.00	\$200.00	\$200.00	\$200.00
Gross Sales	\$30,000,000	\$75,000,000	\$187,500,000	\$328,125,000	\$492,187,500	\$615,234,375	\$707,519,531	\$813,647,461	\$935,694,580	\$1,076,048,767

Assumptions

- Potential users based on number of children at high risk of progressive myopia in the U.S.
- \$400 net monthly price less up to 50% rebates (typical for new products in ophthalmology)
- Eight cartridges per year per patient (“cartridge stretching”)
- Base could be sold to physicians at cost as a possible practice builder

MicroPine Planned Development Timeline



Output from
Analysis of
~240
Patients

If positive and statistically significant,
meet with FDA and continue with one-year
additional safety study

File NDA

Potential
Approval

Introducing the Optejet®

The Only FDA-Approved Ophthalmic Digital Drug Delivery Platform



- Patented digital device platform technology
- Unique, class-leading drug products
- High-value product pipeline addressing areas of significant medical and market need
- Multi-faceted business model with revenue from direct sales and licensing agreements

Optejet® with microdose array print technology

- Designed to address issues with ease-of-use and dosing precision
- Delivers efficacy while improving tolerability and reducing side effects¹
- Digital Optecare™ capabilities²



The Optejet[®] Consists of a Replaceable Cartridge (COGS of \$20) and Durable Base



Proprietary, pre-filled drug cartridge
manufactured by Eyenovia



Optejet uses technology similar to that of inkjet printers to “print” microdroplets of drug onto the eye, using 1/5 of the dose of conventional eye drops to maintain efficacy and minimize tolerability issues



The Optejet Delivers 80% Less Drug Volume Than Eye Droppers

Sufficient for efficacy while improving benefits from reducing excessive exposure to both drugs and preservatives ^{1,2}


Minimizes Excessive Drug Exposure to Ocular Tissues³



Improves Local Tolerability and Decreases Systemic Exposure⁴



Optejet Digital Technology is Optecare™



The Optejet® is capable of automatically tracking usage



OPTECARE:
Multiple Benefits for All Stakeholders

PATIENT

- Reminders to take medicine
- Ability to track compliance progress
- Opportunity for brand-specific encouragement
- May be monetized through app subscription service

PHYSICIAN

- Ability for quicker action with more accurate data
- Opportunity for billing: CPT Code (98980) for monthly check of compliance data

PAYER

- Cost savings: Less likely to have patient on second medication if compliance is the issue
- Better outcomes: Compliance with drug therapy shown to slow disease progression¹

Broad Intellectual Property Portfolio

- Key claims covered with multiple patents
 - 18 US Patents Issued; 8 pending
 - 89 foreign issued; 33 pending
 - Many in effect to 2041
- Clinical data and regulatory approval adds another layer of IP



Multiple Collaborations and Licensing Opportunities In Large Markets

	Target Market	Partner or Status	United States Addressable Market
Collaboration Agreements and Potential Opportunities	Glaucoma	<ul style="list-style-type: none"> EYEN-610 (Open Phase 2 IND for latanoprost in combination with the Optejet) 	\$2.7B ¹
	Acute Dry Eye	<ul style="list-style-type: none"> EYEN-530 (Formosa Pharmaceuticals, potentially superior clinical profile with BID dosing, Phase 3) 	\$0.6B ²
	Chronic Dry Eye	<ul style="list-style-type: none"> EYEN-510 (SGN Nanopharma, faster acting cyclosporin; Phase 2b) EYEN-520 (Senju, peroxisome proliferator-activated receptor delta agonist, Phase 2b) 	\$5.5B ²

Three Product Candidates Addressing Distinct Market Segments in Dry Eye with the Optejet

Foundational Therapy



EYEN-510
MNP Cyclosporine

Faster-acting
Immunomodulator inhibiting
the production of cytokines
involved in the regulation of
T-cell activation.¹

Adjunctive Therapy



EYEN-520
Fonadelpar

Promotes wound healing after
and block corneal fibrosis.^{2,3}
Reduce symptoms of meibomian
gland dysfunction and expression
level of inflammatory cytokines⁴

Flare-Ups



EYEN-530
Clobetasol

Inhibits release of pro-
inflammatory cytokines &
chemokines stimulating the
release of anti-inflammatory
cytokines

Clobetasol Propionate

Ophthalmic Suspension 0.05%

FDA-APPROVED

**For the treatment of post-operative inflammation and pain
following ocular surgery**



Safety Information

IMPORTANT SAFETY INFORMATION: Clobetasol Propionate Ophthalmic Suspension 0.05% is indicated for the treatment of post-operative inflammation and pain following ocular surgery. **CONTRAINDICATIONS:** Most active viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. **WARNINGS AND PRECAUTIONS:** Intraocular Pressure (IOP) Increase: Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. If this product is used for 10 days or longer, IOP should be monitored. Cataracts: Prolonged use of corticosteroids may result in posterior subcapsular cataract formation. Delayed Healing: The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. Corneal and Scleral Melting: In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and where appropriate, fluorescein staining. Bacterial Infections: Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infection. If signs and symptoms fail to improve after 2 days, the patient should be reevaluated. Viral Infections: Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Fungal Infections: Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal culture should be taken when appropriate. **ADVERSE REACTIONS:** Ocular adverse reactions occurring in $\geq 1\%$ of subjects in clinical studies who received clobetasol propionate ophthalmic suspension 0.05% included eye inflammation (2%), corneal edema (2%), anterior chamber inflammation (2%), cystoid macular edema (2%), intraocular pressure elevation (1%), photophobia (1%) and vitreous detachment (1%). Many of these reactions may have been the consequence of the surgical procedure. **PLEASE GO TO CLOBETASOLBID.COM FOR FULL PRESCRIBING INFORMATION**

Ophthalmology's First New Steroid in 15 Years

Physicians now have access to a well-characterized steroid with an advantageous profile

Clobetasol Propionate Ophthalmic Suspension 0.05%, BID

**Fast, Powerful Pain and Inflammation Relief
Post-Ocular Surgery**

Simple BID Dosing Regimen



Minimal Adverse Events

No Insurance Issues. No Call-Backs.

Expected to Provide Near-Term Revenue to Fund Optejet Projects

Clobetasol Utilizes APNT* Technology


Clobetasol Propionate Ophthalmic Suspension 0.05%, BID

Active Pharmaceutical Nanoparticle Technology:

Increases dissolution • Increases bioavailability


Stable and excellent dispersion properties

Active ingredient is milled down with salts or sugars to nanoparticle size




Rapid and Sustained Ocular Pain Relief and Clearance of Inflammation

Percent of Patients with Complete Resolution of Pain at Post-Operative Days 4, 8, and 15



Percent of Patients with Anterior Chamber Cell Count = 0 at Post-Operative Days 8 and 15



Ratio of Patients Pain-Free at Day 15 Post-Op

Summary of Published Studies

A Larger Separation Between Active and Placebo Groups May Not Be Indicative of Relative Efficacy




1. <https://www.sec.gov/Archives/edgar/data/1953530/000119312523206201/d519954d424b3.htm> 2. <https://clobetasolbid.wpenginepowered.com/wp-content/uploads/2024/03/Clobetasol-Precribing-Information.pdf> 3. Evaluate ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery <https://www.clinicaltrials.gov/study/NCT03192150?tab=results> 4. Inveltys Package Insert <https://www.inveltys.com/pdf/inveltys-prescribing-information.pdf> 5. Lotemax package insert <https://www.bausch.com/globalassets/pdf/packageinserts/pharma/lotemax-sm-package-insert.pdf> 6. Durezol package insert https://www.novartis.com/us-en/sites/novartis_us/files/durezol.pdf Head-to-head comparisons are not anticipated.

Ratio of Patients with No Inflammation Day 15 Post Op (ACC Grade = 0)

Summary of Published Studies

A Larger Separation Between Active and Placebo Groups May Not Be Indicative of Relative Efficacy



Low Rate of Adverse Reactions with Clobetasol All of Which Occurred in 2% or Fewer Patients¹

Many of these reactions may have been consequences of the surgical procedure

Eye Inflammation (2%)

Corneal Edema (2%)

Anterior Chamber Inflammation (2%)

Cystoid Macular Edema (2%)

Intraocular Pressure Elevation (1%)

Photophobia (1%)

Vitreous Detachment (1%)

Clobetasol Commercial Strategy

ACTIVATING CUSTOMERS Q3 2024

Sales force is identifying 500 offices who are ready to prescribe and/or stock clobetasol

MINIMIZING BARRIERS TO Rx

Pricing similar to current patient out-of-pocket costs

No insurance necessary

Controlled distribution via e-pharmacy familiar to ophthalmologists

No call backs - No prior authorizations - No hassle to offices

MydCombi™
Ophthalmic Spray
(1% tropicamide and 2.5% phenylephrine)

FDA-APPROVED
For short-term in-office or pre-surgical pupil dilation



Safety Information

IMPORTANT SAFETY INFORMATION: MYDCOMBI (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% is indicated to induce mydriasis for routine diagnostic procedures and in conditions where short term pupil dilation is desired. **CONTRAINDICATIONS:** Known hypersensitivity to any component of the formulation. **WARNINGS AND PRECAUTIONS:** FOR TOPICAL OPHTHALMIC USE. NOT FOR INJECTION. This preparation may cause CNS disturbances which may be dangerous in pediatric patients. The possibility of psychotic reaction and behavioral disturbance due to hypersensitivity to anticholinergic drugs should be considered. Mydriatics may produce a transient elevation of intraocular pressure. Significant elevations in blood pressure have been reported. Caution in patients with elevated blood pressure. Rebound miosis has been reported one day after installation. Remove contact lenses before using. **DRUG INTERACTIONS:** Atropine-like Drugs: May exaggerate the adrenergic pressor response. Cholinergic Agonists and Ophthalmic Cholinesterase Inhibitors: May interfere with the antihypertensive action of carbachol, pilocarpine, or ophthalmic cholinesterase inhibitors. Potent Inhalation Anesthetic Agents: May potentiate cardiovascular depressant effects of some inhalation anesthetic agents. **ADVERSE REACTIONS:** Most common ocular adverse reactions include transient blurred vision, reduced visual acuity, photophobia, superficial punctate keratitis, and mild eye discomfort. Increased intraocular pressure has been reported following the use of mydriatics. Systemic adverse reactions including dryness of the mouth, tachycardia, headache, allergic reactions, nausea, vomiting, pallor, central nervous system disturbances and muscle rigidity have been reported with the use of tropicamide. **PLEASE GO TO MYDCOMBI.COM FOR FULL PRESCRIBING INFORMATION**

MydCombi™


(1% tropicamide and 2.5% phenylephrine) ophthalmic spray

A Milestone for Eyenovia with the First FDA-Approval of Optejet® Technology




Fast, Effective Pupil Dilation Without the Sting or Mess

- Up to eight times less drug used compared with two eye drops
- In two Phase 3 studies, pupil dilation achieved by MYDCOMBI was statistically superior to tropicamide or phenylephrine administered alone
- Nearly all (94%) subject eyes achieved clinically significant effect compared to 78% of eyes administered tropicamide or 1.6% of eyes administered phenylephrine¹
- Only 1 of 131 subjects reported eye stinging upon use



MydCombi Office Outreach

Expanded sales team aiming to introduce MydCombi to 200 additional offices before 2025



Target MydCombi offices have been selected based on interest in Optejet technology

Offices are introduced to MydCombi and Optejet technology by Key Account Manager

Key Account Managers ensure seamless implementation from drop bottles to MydCombi

NASDAQ: EYEN

Our Vision is to Improve Yours



Optejet[®]
Topical Eye Medication Platform Technology

**Major Upcoming Milestone in Pediatric Myopia,
a market worth \$3B in the US and CHINA**

**Two FDA-approved Products that are being
launched by 10-person salesforce**

**Late-Stage Candidates in Dry Eye and Glaucoma,
both are multi-billion dollar markets**

Financial Snapshot - June 2024

Nasdaq: EYEN

Common Shares Outstanding	55.8M
---------------------------	-------

Equity Grants Outstanding Under Stock Plans	7.0M
---	------

Convertible Notes	2.3M
-------------------	------

Warrants	10.9M
----------	-------

Fully Diluted Shares	76.0M
----------------------	-------

Cash	\$2.3M
------	--------

Debt (up to \$5.0M may be paid through the convertible notes)	\$14.8M
---	---------
